Immunomedics, Inc. announced a collaboration with the Carbone Cancer Center at the University of Wisconsin, through Immunomedics entering an agreement with The Prostate Cancer Clinical Trials Consortium (PCCTC), to investigate Immunomedics lead antibody drug conjugate (ADC) product candidate, sacituzumab govitecan, in an investigator-sponsored Phase 2 trial in patients with advanced castration-resistant prostate cancer (CRPC). The therapeutic landscape for men with CRPC has become limited. With the earlier use of agents such as abiraterone acetate and docetaxel, as well as cross resistance to other FDA approved options, including enzalutamide or cabazitaxel, there is a critical need for new therapeutic agents with unique mechanisms of action, stated Joshua M. Lang, MD, Assistant Professor, Division of Hematology/Oncology, University of Wisconsin Carbone Cancer Center, Madison, WI, and the lead investigator of the Phase 2 study. Sacituzumab govitecan is a first in class ADC that targets a molecule known as Trop 2 and has shown clinical activity in patients with mTNBC and advanced UC.